XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Core Viewpoint - Antengene Corporation Limited has successfully expanded the approval and commercial presence of its drug XPOVIO® (selinexor) in multiple APAC markets, including Indonesia, enhancing its position in the biopharmaceutical industry focused on innovative cancer treatments [2][4]. Group 1: Product Approval and Indications - XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia, with its New Drug Application (NDA) approved for three indications related to multiple myeloma and diffuse large B-cell lymphoma [1][2]. - The drug has been approved for multiple indications in ten markets across the APAC region, including health insurance coverage in China, Taiwan, Australia, Singapore, and South Korea [1][3]. Group 2: Market Potential and Expansion - The ASEAN region, with a population exceeding 600 million and steady economic growth, presents significant potential for biomedical development, driven by an aging population and increasing disease burden [4]. - Antengene is actively working to expand its presence in APAC markets to introduce more innovative medicines, aiming to improve healthcare levels and benefit patients in need [4]. Group 3: Mechanism of Action and Development - XPOVIO® is the world's first orally-available, selective XPO1 inhibitor, which promotes the accumulation of tumor suppressor proteins and down-regulates oncogenic proteins, delivering antitumor effects through multiple pathways [6][7]. - Antengene is developing various combination regimens of XPOVIO® for additional indications, including myelofibrosis and endometrial cancer, and is conducting multiple clinical studies in China [5][7]. Group 4: Company Overview and Pipeline - Antengene is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative therapeutics for hematologic malignancies and solid tumors, with a vision of "Treating Patients Beyond Borders" [9]. - Since 2017, Antengene has built a pipeline of 9 oncology assets, obtained 31 investigational new drug (IND) approvals, and submitted 10 NDAs in various Asia Pacific markets [10].